89bio announces completion of enrollment in enliven, the phase 2b trial of pegozafermin for the treatment of nash

219 total patients enrolled; topline data expected in the first quarter of 2023 219 total patients enrolled; topline data expected in the first quarter of 2023
ETNB Ratings Summary
ETNB Quant Ranking